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A B S T R A C T
Purpose: Epilepsy prevalence is significantly higher in people with Intellectual Disability (ID) compared to
people with epilepsy (PWE) from the general population. Increased psychological and behavioural problems,
healthcare costs, morbidity, mortality and treatment resistance to antiepileptic drugs (AEDs) is associated with
epilepsy in ID populations. Prescribing AEDs for PWE and ID is challenging and influenced heavily by studies
conducted with the general population.
Our study compares Lacosamide (LCM) response for the ID population to those from the general population;
using data from an UK based epilepsy database register (EP ID/PDD AED Register).
Methods: Pooled retrospective case notes data for PWE prescribed LCM at 11 UK NHS Trusts were analysed.
Participants were classified as per WHO guidance into groups of moderate-profound ID, mild ID and General
population. Demographics, concomitant AEDs, starting and maximum dosage, exposure length, adverse effects,
dropout rates, seizure frequency were collected. Group differences were reported as odds ratios estimated from
univariable logistic regression models.
Results: Of 232 consented participants, 156 were from the general population and 76 had ID (24 mild, 52
moderate-profound). Twelve month withdrawal rates and reasons, efficacy, side-effects, start and maximum
doses were similar between the groups. Dose titration between baseline and three months was significantly
slower in the ID group (p = 0.02).
Conclusion: There were no differences for LCM outcomes between general and ID groups. Slower LCM titration
in ID populations in the first 3 months was associated with higher retention and lower behavioural side effects as
compared to similar European studies.
1. Introduction
Epilepsy prevalence is approximately 0.6–1.0 % across the world-
wide general population [1]. It is much higher in the intellectual dis-
ability (ID) population, where around 22 % have epilepsy [2]. It is also
estimated that as many as one in four people with epilepsy (PWE) have
an ID [3]. Whilst seizure control for all PWE is initially managed by
licensed Anti-Epileptic Drugs (AEDs), those with ID are excluded from
pre-market systemic trials [4]. Rates of treatment resistance are sig-
nificantly higher in ID populations than general [5]. The scientific
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evidence base for AEDs is therefore predominantly focussed on PWE
from the general population, with limited research on PWE and ID [3].
The clinical picture for PWE and ID is complicated by increased
physical and mental health comorbidities [6], with an average of ten
other co-morbid health issues present [7]. The presentation of seizures
alongside these health issues means accurate diagnosis and AED pre-
scribing is challenging [8]. Increased vulnerability to cognitive and
behavioural side effects, but reduced ability to communicate them,
further complicate the clinical picture [9,8]. There is also limited evi-
dence around quality of life and epilepsy [10,11] and increased po-
tential for drug resistance and interactions [12,13]. Scientific, anec-
dotal, peer, carer and personal feedback are all subsequently utilised
[13] as clinicians are expected to monitor risks and prescribe with
caution [9,8].
Epilepsy has a huge impact on the everyday lives of this complex
and vulnerable population, along with the families and carers who help
look after them [14]. A person with ID is five times more likely than
someone from the general population to have an avoidable emergency
attendance, with seizures responsible for nearly half of such atten-
dances [15]. There is recognition of high rates of premature mortality
in this vulnerable population with 45 % of all premature deaths in
people with ID associated with seizures in the five years prior to demise
[16]. The impact of epilepsy drives an ethical and economic debate for
building an evidence base to help inform decision making around AED
treatment options [17,18,8].
There is also an increasing recognition that the ID population itself
is not a homogenous group. Those with mild ID - as recognised by ICD
10/DSM 5 classification [19,20] - are clinically and socially different in
their presentation from those with moderate to profound ID. Epilepsy
prevalence varies with level of ID, with approximately 10 % of in-
dividuals with mild ID and 30 %–50 % of individuals with moderate,
severe or profound ID diagnosed with epilepsy [2,21,14]. Comorbidity
also varies [6], building an argument for layered guidance around
medication use within the ID population. Epilepsy in those with mod-
erate to profound ID is often more severe and treatment resistant than
mild ID [5].
We report findings here from one arm (lacosamide) of an UK based
database register for PWE and ID [22]. Lacosamide (LCM) is licenced
for the adjunctive treatment of treatment resistant partial-onset seizures
[23] and subsequently for monotherapy for focal epilepsy [18]. LCM
has a novel mode of action as a functionalized amino acid that enhances
the slow inactivation of voltage-gated sodium channels without af-
fecting the fast inactivation of voltage-gated sodium channels. This
inactivation prevents the channel from opening, helping end the action
potential. It has been deemed suitable for prescribing across all PWE,
including those with ID.
A systemic review of fourteen predominantly post license studies of
LCM in 3509 adult patients, demonstrated seizure frequency reduction
of at least 50 % in 18–69 % of patients with refractory focal seizures
(across studies) and potential for seizure termination in refractory
status epilepsy (evidence from three studies) [24]. LCM was also found
to be well tolerated when used in combination with other AEDs. Else-
where Cawello reported a favourable and predictable pharmacokinetic
profile and low potential for drug interactions [25]. Side effects re-
ported for LCM include those common with other AEDs such as dizzi-
ness (22.1 %), vision disturbances (10.1 %), headache (6.8 %) and
nausea (6.3 %) [24].
Despite this substantive evidence - ranging from large scale pro-
spective RCTs [26] to small scale descriptive retrospective studies [27] -
there is limited evidence relating to the use of LCM for PWE and ID.
Three European studies (UK, German and Dutch) drawing on retro-
spective observational data held in clinical records have however been
published (Table 1. Western European Studies of LCM within ID po-
pulations)
The UK study draws data from 19 UK NHS Trusts which had a co-
hort of PWE and ID (n73) within the wider study population [28].
Findings support the safe and effective use of LCM as an adjunctive
therapy in partial-onset seizures for those with ID. They did however
have a slightly lower but not significantly different response rate to
LCM, for people with ID along with less adverse effects and slightly
higher rates of withdrawal, whilst behavioural side effects were rare or
absent [28].
The German study was focused on three years of retention rates of
LCM of 136 adults and children with epilepsy and ID from a single
centre [18]. Retention rates for the first year were similar to that re-
ported by the UK, whilst adverse events were less reported. It is worth
noting that one third of participants pre-study were recognised to have
behavioural issues. No description on effectiveness was provided.
A third similar sized study (n 132) reported on PWE and ID from the
adult population living in three specialised care facilities in the
Netherlands [4]. Retention rates within 12 months were similar to the
UK and German studies. While there was nearly 50 % effectiveness,
adverse effects of LCM were noted in nearly two third (62.9 %) of
participants with one third being behavioural side effects (30 %).
Whilst not dependent on severity of ID, adverse effects were far more
prominent than found in general population studies, whilst physical
side effects were less reported. All studies found concomitant use of
LCM with a sodium channel blocker AED did not influence retention.
2. Methods
‘A register for collecting and measuring outcomes of licensed Anti-
Epileptic Drugs in patients with Epilepsy and Intellectual Disability
and/or Pervasive Developmental Disorders (PDD) ‘Cornwall EP ID/
PDD AED Register’
The data presented in this paper has been drawn from the Cornwall
EP ID/PDD AED Register, a UK NHS based database register for PWE
who have an ID and/or a Pervasive Developmental Disorder PDD. The
database register has NHS ethics approval reference: 14/SC/1270 and
has been adopted as part of the UK National Institute of Health
Research NIHR 31484 portfolio. The data in this paper focusses on the
LCM arm exclusively. Further details of the EP ID/PDD Register can be
found in Appendix 1.
2.1. Consent
Adults aged over 18 and with an epilepsy diagnosis who had been
prescribed LCM (currently taking or withdrawn) at any point prior to
18/12/2017 were approached at eleven UK collaborating sites (one
lead site and 10 NHS Trusts acting as Data Collection Centres). Consent
was either obtained in writing, via a letter sent by attending NHS
clinician, or face-to-face following clinic. For those with ID, the con-
senting process involved providing ‘easy read’ study information and
specially developed consent forms. Where informed consent was not
possible, consent could be gained from a family member or appropriate
carer.
2.2. Data collection and categorisation
All research participants were living in community rather than in-
patient settings. All data collected was obtained from review of NHS
medical records. Records were reviewed for a period of up to fifteen
months. Data were collected at five time points; three months prior to
commencement of LCM, date of LCM commencement and then three,
six and twelve months post commencement. Endpoint was defined as
either one year if the individual continued with LCM treatment or some
point within this period if the drug was withdrawn. Demographic data,
seizure type, concomitant AEDs, starting and maximum dosage of LCM,
length of exposure, adverse effects, dropout rates and seizure frequency
were all collected. Standardised case report forms and data collection
training were provided remotely to Data Collection Centres where
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required with data transferred to a pre-defined standardised Excel
spreadsheet. Participants were allocated non-identifiable ID numbers.
Duration of epilepsy was ascertained in intervals of five years.
Withdrawal rates were estimated as the proportion of people who dis-
continued LCM within the first year. Seizure frequency was recorded as
monthly seizure numbers if evident in medical records, but con-
solidated into percentage improvement from baseline. Outcomes fol-
lowing treatment were defined therefore as “worsening”, “no im-
provement” or improvement equivalent to or greater than “25 %”, “50
%” or “75 %+”, with allocation ascertained by calculating difference in
recorded seizures numbers at endpoint and baseline. Where seizures
were not numerically recorded, frequency and category were de-
termined from clinically recorded impression where appropriate ter-
minology was available.
ID severity was obtained from medical records, with input from GP
health profiles or local clinicians where uncertainty existed [22]. Pre-
existing health conditions were divided into physical, neurodevelop-
mental and mental co-morbidities, with mental health further broken
down into psychotic and non-psychotic conditions. As with previous
AED register arms, side-effect profile for LCM mirrored those detailed in
the UK British National Formulary.
2.3. Analysis
The Chi-squared test was used to test for univariate associations
between outcomes (withdrawal, efficacy, adverse events) and ID group
(general population/mild ID/moderate to profound ID) with p-values
estimated by Monte Carlo simulation. Differences in tolerance, reten-
tion and risk of side-effects between general population patients and ID
groups were further explored using logistic regression analysis.
Potential sources of confounding bias were addressed through adjust-
ment of regression models for demographic factors and baseline se-
verity.
Differences between ID groups were reported as odds ratios esti-
mated from univariable logistic regression models. Age and gender
were added to these models as explanatory factors and the results re-
ported if the adjusted model provided a better fit to the data. The
threshold for statistical significance was p = 0.05. Associations with
0.05 p < 0.1 were reported as marginally statistically significant.
3. Results
Results are presented in Table 2. Two hundred and thirty two people
from 11 UK NHS Trusts (the lead site and 10 Data Collection Centres)
consented for data collection from their medical records. Participants
were made up of 156 PWE from the general population (88 female) and
76 PWE who also had an ID (40 female). Of this ID group 24 had mild
ID (11 female) and 52 had moderate-profound ID (29 female). Age
ranged between 18 and 76 years (with a mean age of 53.2 across all
participants). Only PWE over 18 years of age were consented. Data
were missing for the age of 39 recruits.
The sample size of n = 156 patients without ID and n = 52 patients
with moderate to profound ID provides 90 % power at a significance
level of 5% to detect a group difference in drop-out rates of 25 %, as-
suming a rate of 50 % in the non-ID group. Although the study was
adequately powered to detect large effect sizes, the study was under-
powered to detect small to moderate effect sizes that could still have
clinical implications. By pooling together all ID patients, the study
would be powered to detect a smaller difference in drop-out rates of 19
%.
Existing physical health conditions were evident in 129 (56 %) of all
participants, with similar breakdown marked across different study
cohorts (non-ID n88, 56 %, all ID n41, 54 %). Existing non-psychotic
mental health conditions were recognised in 60 (26 %) of all people,
with psychotic mental health conditions evident in four (2%) and
neurodevelopmental conditions apparent in 51 (22 %). Although psy-
chotic and non-psychotic conditions were similarly evenly spread
across ID and non-ID cohorts (Table 2.), neurodevelopmental disorders
were, as anticipated, far more prominent in the ID population - with
nine (36 %) of those with mild ID and 34 (65 %) of those with mod-
erate-profound ID, compared to only eight (5%) of non-ID PWE. 164 out
of 196 (84 %) of research participants (36 missing) had a history of
Table 1
Western European Studies of LCM within ID populations.
Study Flores et al 2012 (UK) Böttcher et al 2017 (Germany) Brenner et al 2017 (Netherlands)





132 Adult ID patients
(mean age 41.7)




Setting Outpatients (UK) Outpatients and Inpatients (Germany) Inpatients (Netherlands)
Retention
(12 months)
63 % 62 % 64 %
Mean dose 252 mgs 410 mgs 243.6 mgs








(Behavioural side effects 30 %)
Table 2
Demographics and clinical features of patients that underwent Lacosamide
treatment.
All Patients No ID Mild ID Moderate –
Profound ID
Age
< 40 107 (55 %) 56 16 35
40-60 61 (32 %) 49 3 9
60+ 25 (13 %) 25 0 0
Missing (39)
Gender
Male 104 (45 %) 68 13 23
Female 128 (55 %) 88 11 29
Existing conditions
Physical health
Yes 129 (56 %) 88 8 33
No 103 (44 %) 68 16 19
Mental health (non-
psychotic)
Yes 60 (26 %) 44 8 8
No 172 (74 %) 112 16 44
Mental health (psychotic)
Yes 4 (2%) 3 0 1
No 228 (98 %) 153 24 51
Neurodevelopmental
Yes 51 (22 %) 8 9 34
No 181 (78 %) 148 15 18
Lacosamide dose
Mean starting dose 80 mg 74 83 94
Mean Max dose 284 mg 283 302 279
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epilepsy for over 15 years. This included 38 of 41 individuals with
moderate-profound ID, 19 out of 21 with mild ID and 107 out of 134 of
those without ID.
Mean starting dose was 80 mg across all recruits (median 50 mg)
with mean maximum dose 284 mg (median 300 mg). Test of difference
between ID groups were not significant (p = 0.76 for starting dose, p =
0.37 for maximum dose)
Approximately one in five (n43, 20 %) of those for whom with-
drawal data was available (n220 of 232) withdrew from LCM during the
12 months since first prescription (Table 3). This was similar for ID
(n14 – 20 %) and non-ID groups (n29 -19 %), although mild ID PWE (n2
-10 %) were less likely to withdraw than those with moderate-profound
ID (n12 -24 %). The association between withdrawal rate and ID group
was not significant (P = 0.31).
Limited numbers restrict potential for any inference of statistical
significance for reason for withdrawal between ID groups and non-ID
patients (Table 4). However when comparing all ID and non-ID pa-
tients, lack of efficacy was recorded more often as a reason for with-
drawal for ID rather than non-ID patients with over 50 % of ID patient
(7 of 13) withdrawing due to lack of efficacy compared to 17 % of non-
ID patients (5 of 29). Alternatively, increased seizures were recorded
more often for non-ID patients with 31 % for non-ID patients (9 of 29)
compared to 15 % for ID patients (2 of 13).
There was also no difference in efficacy for those with or without ID
(Table 5), with similar recorded data relating to the effect of LCM on
people’s seizures (p = 0.93 for association between ID group and ef-
ficacy). With missing data removed, greater than 50 % seizure im-
provement was evident in 43 % (48 of 111) non-ID, 44 % (8 of 18) in
the mild ID and 38 % (16 of 42) of moderate-profound ID. Seizure
improvement was similar across groups. Efficacy data was missing for
61 participants. This is likely due to minimal or absent recording of
seizure frequency data in medical records. Forty four of these in-
dividuals remained on the medication with nine withdrawing (with-
drawal data was missing for the remaining eight).
Physical health side-effects were evident in 30 % (n70) of the total
cohort, whilst mental health side-effects were evident in only 3% (n 5).
As with other findings, prevalence of physical and mental health side-
effects was a similar across study cohorts (p = 0.21 and 1.00 respec-
tively for associations with ID group). For the full ID cohort physical
health side effects were reported in 22 % (n17) and 4% (n3) PWE
(Table 6).
Data were also pooled to compare full ID population (mild ID and
Moderate-Profound ID) with the non-ID population for the analysis
detailed above. Data comparisons were non-significant apart from the
analysis of titration data at different time points (Table 7.). Whilst mean
(and median) increases in dose from baseline to the maximum dose are
similar for both groups (Non-ID and all ID patients), the difference
between dose at baseline and 3 months later was found to be sig-
nificantly larger in the non-ID population (p = 0.02).
4. Discussion
The research reported in this paper uses the standardised EP ID/
PDD AED Register to present a real world observational study of LCM
use in PWE from the general population and PWE with ID. Analysis is
focussed on studying similarities and differences between and across
participant groups with the ID population split into those with mod-
erate-profound ID and those with mild ID. Further analysis comparing
all participants with ID and all non-ID participants was undertaken.
The overriding theme within the data reported is the similarities in
responses to LCM across the different participant groups. Seizure fre-
quency and intensity (efficacy), withdrawal rates within twelve months
and reported side-effects across PWE from the general population and
PWE who have mild or moderate-profound ID are comparable. Starting
dose and maximum dose of LCM treatment were similar across the
different populations. Data reported on the measured metrics were also
similar when ID groups were combined and compared with the non-ID
group. A major finding is a possible association to high retention rates
in the ID population linked to slower titration in the first three months
of inception. This provides evidence to what has been of late suspected
that people with ID benefit from slower titration of medication than
suggested by the drug manufacturers or licencing authorities with the
preliminary goal being retaining the drug.
Our data builds on the limited but growing evidence base around
the use of LCM with people who have ID. Our methodology is similar to
previous research detailed in our introduction [18,4,28]. The pre-
sentation of ID and general population data alongside following iden-
tical collection methods is a particular strength our study. Despite
Table 3
Withdrawal.
All patients No ID Mild ID Moderate – Profound ID
Missing 12 (5%) 7 3 2
Yes 43 (19 %) 29 2 12
No 177 (76 %) 120 19 38
Table 4
Reason for withdrawal.
All patients No ID Mild ID Moderate – Profound ID
Missing 12 7 3 2
No withdrawal 177 120 19 38
Increased seizures 11 9 0 2
Intolerable 14 11 1 2
Lack of efficacy 12 5 1 6
Other 5 4 0 1
Table 5
Efficacy.
All patients No ID Mild ID Moderate – Profound ID
Missing 61 (26 %) 45 6 10
Worsening 27 (12 %) 19 2 6
No change 48 (21 %) 29 6 13
25 % improvement 24 (10 %) 15 2 7
50 % improvement 30 (13 %) 21 2 7
75 % improvement 42 (18 %) 27 6 9
Table 6
Side-effects.
All patients No ID Mild ID Moderate – Profound ID
Physical
Yes 70 (30 %) 53 5 12
No 162 (70 %) 103 19 40
Mental
Yes 8 (3%) 5 1 2
No 224 (97 %) 151 23 50
Table 7
Titration comparison (pooled ID participants).
Non-ID ID patients (all) p-value
Baseline to 3 months
Mean 157 mg 123 mg 0.02
Median 150 mg 125 mg
Baseline to max dose
Mean 209 mg 196 mg 0.54
Median 200 mg 200 mg
J. Allard, et al. Seizure: European Journal of Epilepsy 76 (2020) 161–166
164
similarities across the all four studies there are also variations when
comparing the data which merit further discussion.
Firstly, the twelve month withdrawal rate for our ID participants is
smaller than that reported in the three other studies, with only 20 %
withdrawing and 76 % remaining on the study medication (4%
missing), compared to a 62 %–64 % retention across other studies
[18,4,28]. Interesting the general population cohort in the UK study
was also less likely to stay on LCM for 12 months compared to our
general population cohort (68 % compared to 77 %). The fact that the
UK study reported from a data collection period five years before our
study, when LCM was relatively new to the market, is worth noting. Our
data reported around titration differences between ID and general po-
pulation, illustrating a cautious approach to initial LCM prescription in
the ID population. Titration data from the other studies have not been
reported but are expected to have followed the manufacturers or li-
cencing authorities’ guidance.
The UK study also looked at seizure improvement in a similar way to
our study, reporting more than 50 % improvement in 32.7 % of ID PWE,
smaller than the 42 % of PWE in our ID cohort. The Dutch study re-
ported undefined ‘seizure reduction’ in 48.5 % while the German study
did not report seizure reduction.
There are clearer differences in relation to side effects reported
across the studies. The German studies of overall numbers (19 %) are
similar to our findings and the rare reports of mental health/beha-
vioural reported within our study mirror those in the UK study.
However the UK study reported far more physical health side-effects,
whilst the Dutch study reports much higher overall side-effect (63 %)
and behavioural side-effects (30 %). The German study talks of high
levels of behavioural concerns (31.6 %) but does not explain whether
they were baseline or associated with treatment.
Whilst some of the above comparisons are intriguing, the clear
differences across participant datasets, implies that any inference par-
ticularly of generalizability must be made cautiously. Data were col-
lected for different time periods. Differences in the age of cohorts, pa-
tient settings and ID type will have also likely impacted on the data.
Factors such as prescriber background, prescribing tendencies and in-
stitutionalization care are potential confounders. As with all studies
which draw retrospectively from clinical records, the quality of the data
reported is also dependent on what is available to be captured across
different electronic or paper medical records. Again this may vary with
different healthcare systems and cultures.
There are also other specific limitations for our study which should
be considered. As detailed above we only collected data from partici-
pants who consented to data collection from their medical records. Data
Collection Centres were asked to approach all PWE currently or pre-
viously prescribed LCM but had varying resources to do this and we do
not have data on specific recruitment rates of each centre. It could be
argued that those still on LCM may have been more likely to consent to
the study and that this may impact on our higher retention rates when
compared to the other studies. Lastly, collecting data for PWE and ID is
particularly challenging. This is due to the possibility for seizure ac-
tivity or side-effects being unnoticed or underreported as a result of
multiple comorbidities and communication difficulties.
5. Conclusions
Despite the limitations detailed above, the findings reported here,
and comparisons with broadly similar data from other European ret-
rospective studies of patient medical records, help address the evidence
gap around the safe and effective use of LCM within the ID population.
Our data suggests that clinicians may expect similar results in people
with ID in relation to efficacy, withdrawal, impact on seizures and side-
effects when considering prescribing of LCM as with the general po-
pulation. Our data also suggests that clinicians from our DCCs appear to
initially proceed with caution when titrating for LCM within the first
three months of prescription and do not increase the dose as rapidly as
they do for the general population. Whilst it cannot be concluded that
this titration impacts on the high retention in our ID population, its
association is a worthwhile clinical point to keep in mind.
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